Factor IXa Inhibitor Compounds Resolving Specificity Efficacy Trade-off
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively regulate Factor IXa activity, leading to uncontrolled thrombus formation and increased risk of thrombosis, with existing inhibitors having limitations in specificity and efficacy.
Innovation Solution
Development of a novel class of compounds, specifically those of Formula (I), which are designed to inhibit Factor IXa, offering prophylactic and therapeutic options for preventing thrombosis and associated conditions by selectively targeting Factor IXa without affecting other coagulation factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Factor IXa inhibitors are used, then some inhibition effect is achieved, but specificity and efficacy are limited
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features at particular positions to enhance both binding affinity and selectivity. The compounds of Formula (I) incorporate specific substituent patterns and molecular architectures that target Factor IXa with high precision while maintaining strong inhibition效果
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types, positions, and configurations in the compounds of Formula (I). This allows optimization of the balance between inhibition potency and specificity for Factor IXa, resolving the contradiction between efficacy and selectivity
2Object-affected harmful factors
If Factor IXa activity is inhibited, then thrombus formation is reduced, but bleeding risk may increase
Solution Approach 1:
The patent applies partial action by developing Factor IXa inhibitors that provide sufficient inhibition to prevent thrombus formation in pathological conditions while maintaining safety margins. The compounds are designed to achieve therapeutic effect without complete suppression of coagulation, thereby minimizing bleeding risk
Solution Approach 2:
The patent incorporates feedback mechanisms through the design of reversible inhibitors that allow physiological regulation. The compounds of Formula (I) can be adjusted in dosage and have reversible binding characteristics, enabling the body's natural homeostatic mechanisms to prevent excessive anticoagulation and bleeding
Data Source
AI summary
The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.